Developing Novel Car T Cell Therapy Approaches to Treat Prostate Cancer

Variable cellular and radiobiological effects of [177Lu]Lu-PSMA-I&T in patient-derived models of prostate cancer

IM Everard, MJ de Veer, EM Kwan, NL Lister, S Keerthikumar, A Ryan, D Sivaratnam, MB Haskali, GP Risbridger, LH Porter, RA Taylor

2026-12-01

Background: [¹⁷⁷Lu]Lu-PSMA radioligand therapy targets metastatic castration-resistant prostate cancer by delivering ra..

p-AKT Protein Expression Predicts Response to AKT Inhibitor Combined with Docetaxel Therapy in Adenocarcinoma and Neuroendocrine Prostate Cancer

HW Gomes, NL Lister, S Keerthikumar, B Niranjan, MG Richards, A Ryan, EM Kwan, GP Risbridger, RA Taylor

2025-07-01

Purpose: AKT inhibitors, such as capivasertib, have shown activity in specific patients with metastatic castration-resistant prost..

Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies

LH Porter, SG Harrison, GP Risbridger, Natalie Lister, RA Taylor

2024-10-01

Prostate cancer is primarily hormone-dependent, and medical treatments have focused on inhibiting androgen biosynthesis or signali..

Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models

LH Porter, JJ Zhu, NL Lister, SG Harrison, S Keerthikumar, DL Goode, RQ Urban, DJ Byrne, A Azad, I Vela, MS Hofman, PJ Neeson, PK Darcy, JA Trapani, RA Taylor, GP Risbridger

2023-12-01

Chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for hematological malignancies. However, CAR T ce..

The future of patient-derived xenografts in prostate cancer research

MG Lawrence, RA Taylor, GB Cuffe, LS Ang, AK Clark, DL Goode, LH Porter, C Le Magnen, NM Navone, JA Schalken, Y Wang, WM van Weerden, E Corey, JT Isaacs, PS Nelson, GP Risbridger

2023-06-01

Patient-derived xenografts (PDXs) are generated by engrafting human tumours into mice. Serially transplantable PDXs are used to st..